⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2026International Journal of Infectious DiseasesOpen Access

Efficacy and Safety of Long-Acting Lenacapavir for HIV Treatment and Prevention: A Systematic Review of Randomized Trials

Blessed T Mukuhlani Rufin K. Assaré

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the efficacy and safety of long-acting lenacapavir in HIV treatment and prevention.
Conducted systematic review of randomized trials
Analyzed data on viral suppression rates
Assessed safety profiles of lenacapavir
Lenacapavir achieved high rates of viral suppression
Demonstrated favorable safety profile
Effective for both treatment and prevention of HIV

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Study demonstrate high viral suppression with lenacapavir for HIV treatment, indicating its effectiveness and safety.

Abstract

Lenacapavir achieved high viral suppression in randomized treatment

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mukuhlani et al. (2026) studied this question.

synapsesocial.com/papers/69c2294caeb5a845df0d38fa https://doi.org/10.1016/j.ijid.2026.108580

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial2024 · 42 citations
2Long-Acting Lenacapavir and Cabotegravir and Viral Suppression Among People With HIVCase Report · 2026
3Current Evidence on Lenacapavir, a Long-Acting Twice-Yearly Injectable for HIV Prevention: A Scoping ReviewReview · 2026
4Lenacapavir at the Spatiotemporal Limit: Tissue Pharmacokinetics, Pharmacokinetic Tail Dynamics, and the Emergence of Capsid Resistance in Long-Acting HIV PreventionLate-Phase Clinical Trial · 2026
5 Efficacy and safety of lenacapavir containing regimens in highly experienced HIV-infected patients with multidrug-resistance: real-word results from the French Compassionate Use ProgramOriginal Research · 2026 · 1 citations

More related papers

Commentary on PURPOSE-1 and PURPOSE-2 trials of lenacapavir: a breakthrough in HIV prevention2026
A Review of Lenacapavir Act as Caspid Inhibitor2025
Lenacapavir: a transformative advance in HIV therapy and prevention—promise, access, and equity in Africa2026

More from International Journal of Infectious Diseases

2-Deoxy-D-Glucose in a Human Rhinovirus Challenge Model: a Randomised, Double-blind Placebo-controlled phase 2a clinical trial.Tue,
Prediction of response to Buruli ulcer treatment shortening with novel beta-lactam-containing antimicrobial combinationsThu,